cyclic-guanosine-monophosphate-adenosine-monophosphate and Ovarian-Neoplasms

Despite major advancements in immunotherapy among a number of solid tumors, response rates among ovarian cancer patients remain modest. Standard treatment for ovarian cancer is still surgery followed by taxane- and platinum-based chemotherapy. Thus, there is an urgent need to develop novel treatment options for clinical translation.. Our approach was to analyze the effects of standard chemotherapy in the tumor microenvironment of mice harboring orthotopic, syngeneic ID8-Vegf-Defb29 ovarian tumors in order to mechanistically determine a complementary immunotherapy combination. Specifically, we interrogated the molecular and cellular consequences of chemotherapy by analyzing gene expression and flow cytometry data.. These data show that there is an immunosuppressive shift in the myeloid compartment, with increased expression of IL-10 and ARG1, but no activation of CD3. This work highlights the importance of CD4

Topics: Adaptive Immunity; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; CD4-Positive T-Lymphocytes; Combined Modality Therapy; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunity, Innate; Interleukin-10; Mice; Molecular Targeted Therapy; Nucleotides, Cyclic; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome; Tumor Microenvironment; Xenograft Model Antitumor Assays